Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
9.63
-0.27 (-2.73%)
At close: Dec 5, 2025, 4:00 PM EST
10.50
+0.87 (9.03%)
After-hours: Dec 5, 2025, 7:23 PM EST
Tango Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 66.5 | 42.07 | 36.53 | 24.86 | 37.04 | 7.66 | |
| Revenue Growth (YoY) | 53.29% | 15.17% | 46.93% | -32.89% | 383.83% | -68.94% | |
| Cost of Revenue | 134 | 143.92 | 115.2 | 105.91 | 77.64 | 49.99 | |
| Gross Profit | -67.5 | -101.85 | -78.67 | -81.05 | -40.59 | -42.34 | |
| Selling, General & Admin | 42.84 | 43.75 | 35.5 | 30.03 | 17.6 | 9.87 | |
| Operating Expenses | 42.84 | 43.75 | 35.5 | 30.03 | 17.6 | 9.87 | |
| Operating Income | -110.34 | -145.6 | -114.17 | -111.07 | -58.19 | -52.2 | |
| Interest & Investment Income | 5.76 | 7.89 | 6.62 | 1.46 | 0.5 | 0.11 | |
| Other Non Operating Income (Expenses) | 6.01 | 7.61 | 5.94 | 1.49 | -0.25 | 0.12 | |
| Pretax Income | -100.41 | -130.09 | -101.61 | -108.12 | -57.94 | -51.97 | |
| Income Tax Expense | 0.11 | 0.21 | 0.13 | 0.05 | 0.29 | - | |
| Net Income | -100.52 | -130.3 | -101.74 | -108.18 | -58.24 | -51.97 | |
| Net Income to Common | -100.52 | -130.3 | -101.74 | -108.18 | -58.24 | -51.97 | |
| Shares Outstanding (Basic) | 111 | 109 | 95 | 88 | 62 | 32 | |
| Shares Outstanding (Diluted) | 111 | 109 | 95 | 88 | 62 | 32 | |
| Shares Change (YoY) | 2.50% | 15.50% | 7.69% | 41.40% | 94.50% | 255.37% | |
| EPS (Basic) | -0.91 | -1.19 | -1.08 | -1.23 | -0.94 | -1.63 | |
| EPS (Diluted) | -0.91 | -1.19 | -1.08 | -1.23 | -0.94 | -1.63 | |
| Free Cash Flow | -146.77 | -132.26 | -119.51 | -116.77 | -61.36 | 68.97 | |
| Free Cash Flow Per Share | -1.33 | -1.21 | -1.26 | -1.33 | -0.99 | 2.16 | |
| Gross Margin | -101.50% | -242.10% | -215.38% | - | -109.59% | - | |
| Operating Margin | -165.91% | -346.09% | -312.57% | -446.79% | -157.09% | -681.82% | |
| Profit Margin | -151.15% | -309.73% | -278.55% | -435.14% | -157.21% | -678.84% | |
| Free Cash Flow Margin | -220.70% | -314.38% | -327.18% | -469.72% | -165.66% | 900.84% | |
| EBITDA | -107.91 | -143.1 | -111.76 | -109.46 | -57.29 | -51.48 | |
| EBITDA Margin | -162.27% | - | - | - | -154.67% | - | |
| D&A For EBITDA | 2.42 | 2.5 | 2.42 | 1.61 | 0.9 | 0.72 | |
| EBIT | -110.34 | -145.6 | -114.17 | -111.07 | -58.19 | -52.2 | |
| EBIT Margin | -165.91% | - | - | - | -157.09% | - | |
| Revenue as Reported | 66.5 | 42.07 | 36.53 | 24.86 | 37.04 | 7.66 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.